ArticleThe Pan African medical journal2025
Vaccine-induced immune thrombotic thrombocytopenia in Tunisia following AstraZeneca COVID-19 vaccination: a case report.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines against SARS-CoV-2 were rapidly developed to combat the COVID-19 pandemic. Rare cases of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) have been reported after the AstraZeneca COVID-19 vaccination. We present a case of a 51-year-old healthy man who developed fever, unconsciousness, thrombocytopenia, multiple thromboses, and macrophage activation syndrome one week after receiving the first dose of the AstraZeneca COVID-19 vaccine. Initial anti-PF4 antibody tests were negative, but subsequent ELISA confirmed their presence. Despite plasma exchange and steroid therapy, the patient developed neurological deficits, gastrointestinal hemorrhage, multiple cerebral infarcts, and died. This case illustrates the risk of fatal vaccine-induced immune thrombotic thrombocytopenia after an AstraZeneca COVID-19 vaccination and emphasizes the need for early recognition and specialized testing, including PF4 ELISA, to improve patient outcomes. Reporting such cases raises awareness, supports timely diagnosis, and guides appropriate management while reinforcing the importance of vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.